Scrip's Stock Tracker: Another volatile month in June
This article was originally published in Scrip
Executive Summary
When will this roller coaster ride end? Scrip's Stock Tracker described May as a month of continued uncertainty in the world’s capital markets, and the picture remained volatile in June as well. The end of the month gives a chance to review performance in June, as well as the first half of 2008, with a particular focus on the 10 global pharma and five US biotech stocks tracked each month by Scrip. Independent consultant Emma Palmer reviews the month.
You may also be interested in...
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.
Theravance's Gut-Selective JAK Inhibitor Disappoints In Ulcerative Colitis Study
Top-line results from a Phase IIb study of Theravance’s potential gut-selective JAK inhibitor izencitinib have not matched expectations, and results from a similar early-stage study in Crohn’s disease with the Janssen-partnered candidate are now awaited at the end of the year or in early 2022.